Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment
M. Trapero-Marugán MD
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Search for more papers by this authorJ. Mendoza MD
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Search for more papers by this authorJ. A. Moreno Monteagudo MD
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Search for more papers by this authorM. Chaparro MD
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Search for more papers by this authorL. García-Buey MD
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Search for more papers by this authorL. González-Moreno MD
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, Madrid, Spain
Search for more papers by this authorM. J. Borque BSc
Molecular Biology Unit, Hospital Universitario de La Princesa, Madrid, Spain
Search for more papers by this authorR. Moreno-Otero MD
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Search for more papers by this authorM. Trapero-Marugán MD
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Search for more papers by this authorJ. Mendoza MD
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Search for more papers by this authorJ. A. Moreno Monteagudo MD
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Search for more papers by this authorM. Chaparro MD
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Search for more papers by this authorL. García-Buey MD
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Search for more papers by this authorL. González-Moreno MD
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, Madrid, Spain
Search for more papers by this authorM. J. Borque BSc
Molecular Biology Unit, Hospital Universitario de La Princesa, Madrid, Spain
Search for more papers by this authorR. Moreno-Otero MD
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Search for more papers by this authorSummary
What is known and Objective: Interferon-alfa-based therapy is effective in the treatment of Hepatitis C. However, some patients fail to respond and others relapse, after initially responding. Our objective was to assess the efficacy, safety and predictive factors for sustained virological response (SVR) to peginterferon plus ribavirin in chronic hepatitis C patients who failed to interferon-alfa (IFNα)-based therapy.
Methods: Seventy-five consecutive patients who failed to IFNα-based therapy were retreated with peginterferon plus ribavirin. Of these patients, 85% were infected by genotype 1. The primary endpoint was SVR.
Results and Discussion: Of 75 non-responder (n = 54) or relapser patients (n = 21), 50 were previously treated with IFNα-monotherapy and 25 with IFNα plus ribavirin. Global SVR rate was 41·3%: for patients re-treated with IFNα the response was 48% whilst for those retreated with IFNα plus ribavirin, it was 28%. For previous non-responders the SVR rate was 37% and for relapsers it was 52·4%.
What is new and Conclusion: Retreatment with peginterferon plus ribavirin is an effective option for some chronic hepatitis C non-responder or relapser patients. Higher SVR rate was achieved in relapsers and in those patients who received IFNα monotherapy previously.
References
- 1 Consensus statement (1999) EASL International Consensus Conference on hepatitis C, Paris, 26–27 February 1999. Journal of Hepatology, 31(Suppl 1), 3–8.
- 2 NIH Consensus Statement on Management of Hepatitis C (2002) NIH Consens State Science Statements, 19, 1–46.
- 3 Pawlotsky JM (2005) Current and future concepts in hepatitis C therapy. Seminars in Liver Disease, 25, 72–83.
- 4 Bonkovsky HL, Clifford BD, Smith LJ, Allan C, Banner B (1996) High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial. Digestive Diseases and Sciences, 41, 149–154.
- 5 Spadaro A, Freni MA, Ajello A, Alessi N, Barbaro E, Resta ML, Ferrau O (1999) Interferon retreatment of patients with chronic hepatitis C. A long-term follow-up. Hepato-Gastroenterology, 46, 3229–3233.
- 6 Picciotto A, Campo N, Brizzolara R et al. (1999) Interferon retreatment in chronic hepatitis C: which patients to choose, and what schedule to use. European Journal of Gastroenterology & Hepatology, 11, 649–653.
- 7 Cummings KJ, Lee SM, West ES et al. (2001) Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA, 285, 193–199.
- 8 Barbaro G, Di Lorenzo G, Soldini M et al. (1998) Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study. American Journal of Gastroenterology, 93, 2445–2451.
- 9 Barbaro G, Di Lorenzo G, Belloni G et al. (1999) Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. American Journal of Medicine, 107, 112–118.
- 10 Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G (1997) Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology, 26, 137S–142S.
- 11 Barbaro G, Barbarini G (2002) Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study. European Journal of Gastroenterology & Hepatology, 14, 477–483.
- 12 Cornberg M, Hadem J, Herrmann E et al. (2006) Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. Journal of Hepatology, 44, 291–301.
- 13 Chemello L, Cavalletto L, Donada C et al. (1997) Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology, 113, 1654–1659.
- 14 Kjaergard LL, Krogsgaard K, Gluud C (2001) Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. British Medical Journal, 323, 1151–1155.
- 15 Min AD, Jones JL, Esposito S et al. (2001) Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone. American Journal of Gastroenterology, 96, 1143–1149.
- 16 Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB (2001) Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology, 33, 231–240.
- 17 San Miguel R, Guillen F, Cabases JM, Buti M (2002) Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon. Alimentary Pharmacology & Therapeutics, 16, 1611–1621.
- 18 Camma C, Bruno S, Schepis F et al. (2002) Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut, 51, 864–869.
- 19 Enriquez J, Gallego A, Torras X et al. (2000) Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. Journal of Viral Hepatitis, 7, 403–408.
- 20 Lo Iacono O, Castro A, Diago M et al. (2000) Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy. Alimentary Pharmacology & Therapeutics, 14, 463–469.
- 21 Diago M, Lujan M, Valeros D et al. (2001) Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferon. Revista Eespanola de Enfermedades Digestivas, 93, 353–363.
- 22 Marco VD, Almasio P, Vaccaro A et al. (2000) Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. Journal of Hepatology, 33, 456–462.
- 23 Papatheodoridis GV, Cholongitas E (2004) Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. Journal of Viral Hepatology, 11, 287–296.
- 24 Shiffman ML, Di Bisceglie AM, Lindsay KL et al. (2004) Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology, 126, 1015–1023; discussion 947.
- 25 Jensen DM, Marcellin P (2005) Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. European Journal of Gastroenterology & Hepatology, 17, 899–904.
- 26 Global surveillance and control of hepatitis C (1999) Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. Journal of Viral Hepatology, 6, 35–47.
- 27 Lee WM, Dienstag JL, Lindsay KL et al. (2004) Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Controlled Clinical Trials, 25, 472–492.
- 28 Marcellin P, Freilich B, Andreone P et al. (2005) Interim safety analysis of patients enrrolled in the randomized, international retreatment with Pegasys in patients not responding to prior peginterferon alfa-2b/ribavirin (RBV) combination therapy (REPEAT) study. Hepatology, 42, 657A.
- 29 Marrache FRM, Consigny Y, Cazalshaten D et al. (2003) Safety and efficacy of peginterferon alpha2b plus ribavirin in precirrhotic and cirrhotic patients with chronic hepatitis C. Gastroenterology, 124, 123.
- 30 Marrache F, Consigny Y, Ripault MP et al. (2005) Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. Journal of Viral Hepatology, 12, 421–428.
- 31 Dalke DDJ, Mailiard M, Monsour H (2004) Peginterferon alfa-2b plus ribavirin for retreatment of chronic hepatitis C. Gastroenterology, 126, 123.
- 32 Gaglio PJCJ, Zimmerman D, Heller L, Brown RSJ (2004) Pegylated interferon (alpha-2b) and ribavirin (rebetol) for the treatment of HCV infected patients who failed prior therapy: sustained response data. Gastroenterology, 126, M1230.
- 33 Bapin CF-PP, Hachemane S, Larrey D (2003) Retreatment with pegylated interferon alpha 2b and ribavirin in patients with chronic hepatitis c non responders to interferon monotherapy or interferon and ribavirin combination. A prospective randomized pilot study of two regimens: induction versus regular dose pegylated interferon. Gastroenterology, 124, M1231.
- 34 Diago MRM, Crespo J, Olveira A et al. (2003) High-dose peginterferon alfa2a (40 KD) (Pegasys) and ribavirin (copegus) in patients infected with hepatitis c virus (HCV) genotype 1 who failed to respond to interferon alfa and ribavirin. Hepatology, 38, 740A.
- 35 Sherman MYE, Deschenes M, Kradjen M et al. (2005) Peginterferon alfa2a (40 kD) plus ribavirin in chronic hepatitis c patients who failed previous interferon-based therapy: results of a multicentre open-label expanded access program in Canada. Journal of Hepatology, 42, 220.
- 36 Sherman M, Yoshida EM, Deschenes M et al. (2006) Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut, 55, 1631–1638.
- 37 Taliani GAA, Capanni M, Ferrari C et al. (2005) Pegylated interferon alfa2b plus ribavirin in the re-treatment of patients non responsive to IFN/RBV. Journal of Hepatology, 42, 222.
- 38 Rothstein KKR, Fernandez A, Singh S et al. (2005) High dose consensus interferon and ribavirin is effective for treatment of chronic hepatitis c infection in patients who are resistant to peg-interferon and ribavirin. Gastroenterology, 128, S1536.
- 39 Krawitt EL, Ashikaga T, Gordon SR, Ferrentino N, Ray MA, Lidofsky SD (2005) Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. Journal of Hepatology, 43, 243–249.
- 40 Jacobson IM, Gonzalez SA, Ahmed F et al. (2005) A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. American Journal of Gastroenterology, 100, 2453–2462.
- 41 Carnicer F, Zapater P, Gutierrez A, Garcia A, Ruiz F, Lopez M (2005) Treatment with pegylated interferon alpha-2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin. Revista Eespanola de Enfermedades Digestivas, 97, 306–316.
- 42 Shiffman ML (2004) Retreatment of chronic hepatitis C virus infection in patients who failed to achieve sustained virologic response. Minerva Gastroenterology & Dietology, 50, 37–49.
- 43 Taliani G, Gemignani G, Ferrari C et al. (2006) Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology, 130, 1098–1106.
- 44 Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, Angarano G (2008) Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b. Drugs, 68, 791–801.
- 45 Poynard T, Colombo M, Bruix J et al. (2009) Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology, 136, 1618–1628.
- 46 Sarrazin CRR, Wagner F, Forestier N et al. (2007) SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alfa-2b for genotype 1 non-responders. Gastroenterology, 132, 1270–1278.
